DGAP-News: Apricus Biosciences to Present at the FSX Investor Conference in San Francisco on April 28, 2011

Apricus Biosciences, Inc.

27.04.2011 19:17
—————————————————————————

SAN DIEGO, April 27, 2011 (GLOBE NEWSWIRE) — Apricus Biosciences (–Apricus
Bio–) (Nasdaq:APRI) today announced that Ed Cox, Vice President Corporate
Development and Investor Relations, will present at the FSX (Financial Services
Exchange, Inc.) investors conference being held at the Ritz Carlton in San
Francisco from April 28-30, 2011. Mr. Cox–s presentation is scheduled for
tomorrow, April 28, 2011 and will not be available in live webcast, but a
replay will be available on the Company–s website.

FSX is the premier investment conference organization in the United States,
hosting quarterly investment conferences around the country, providing
opportunities for networking and one-on-one communication between independent
broker/dealers and companies seeking exposure or funding. FSX conferences also
provide a forum for direct investment programs, mutual funds, and asset
management companies. For more information visit: www.fsxone.com.

About Apricus Biosciences

Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has
leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes.

Revenues and growth are driven from out-licensing of this technology for the
development and commercialization of such compounds to pharmaceutical and
biotechnology companies worldwide. In addition, the Company is seeking to
monetize its existing product pipeline, including its first product, Vitaros(r),
approved in Canada for the treatment of erectile dysfunction, which is
currently expected to be available on the Canadian market in 2011, as well as
compounds in development from pre-clinical through Phase III, currently focused
on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain,
Anti-Infectives, Diabetes and Cosmeceuticals among others.

For further information on Apricus Bio, visit http://www.apricusbio.com and for
information on its subsidiaries please visit www.nexmedusa.com or
www.bio-quant.com. You can also receive information at
http://twitter.com/apricusbio and http://facebook.com/apricusbio.

Apricus Bio–s Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop products and
product, to successfully commercialize such products and product candidates and
to achieve its other development, commercialization and financial goals.
Readers are cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the forward-looking
statements contained herein. Readers are urged to read the risk factors set
forth in the Company–s most recent annual report on Form 10-K, subsequent
quarterly reports filed on Form 10-Q and other filings made with the SEC.
Copies of these reports are available from the SEC–s website or without charge
from the Company.

CONTACT: Apricus Bio Contacts:
Edward Cox, V.P. Investor Relations
Apricus Biosciences
(858) 848-4249
ecox@apricusbio.com

Apricus Bio Investor Relations:
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX

27.04.2011 Dissemination of a Corporate News, transmitted by DGAP –
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP–s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

—————————————————————————

Language: English
Company: Apricus Biosciences, Inc.

United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:

End of Announcement DGAP News-Service

—————————————————————————